The system that allows for low-cost versions of biologic drugs is in peril if Obamacare is reversed in the wake of Justice Ruth Bader Ginsburg’s death.
The Affordable Care Act created a pathway for companies to make biosimilars—generic versions of biologic drugs that are very similar, though not identical, to the originals—without having to jump through costly hoops associated with getting a novel medicine approved.
Biologic drugs are produced from living organisms or contain components thereof to create effective therapies. For example, AbbVie Inc.'s Humira is a biologic that treats conditions such as rheumatoid arthritis and Crohn’s Disease, while Genentech ...